Last edition
News about
Enspire DBS Therapy Raises USD 10.3M Series B1 to Advance Post-Stroke Neuromodulation Trial
The funding led by Genesys Capital will support continued enrollment in Enspire’s pivotal restore clinical trial evaluating deep brain stimulation combined with rehabilitation for stroke recovery.
Thryv Therapeutics Initiates Wave II Phase II/III Trial for Long QT Syndrome Type 2
Thryv Therapeutics has launched the Wave II Phase II/III trial to evaluate THRV-1268, an oral SGK1 inhibitor, as a potential disease-modifying therapy for adults with Long QT Syndrome Type 2.
Risa Labs Raises USD 11.1M Series A to Scale AI OS for Oncology Care
The funding led by Cencora Ventures and Optum Ventures will accelerate nationwide deployment of Risa’s AI-driven platform to streamline oncology workflows, reduce delays and improve patient access to cancer therapies.
Bionpharma Wins FDA Approval for Etravirine Tablets in Partnership with STEERLife
The US FDA approval clears the way for Bionpharma to market its generic Etravirine tablets in the US, expanding patient access to a cost-effective HIV treatment option.
Thermo Fisher and NVIDIA Partner to Advance AI-Driven Scientific Instrumentation
Under the partnership, Thermo Fisher Scientific and NVIDIA will connect laboratory instruments and data systems with advanced AI capabilities to streamline operations and accelerate scientific research.
Biocon Receives US FDA Approval for Everolimus Tablets for Oral Suspension
Biocon has secured US FDA approval for Everolimus Tablets for Oral Suspension, enhancing its portfolio of vertically integrated drug products and expanding treatment options for patients in key markets.
WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing
The UK regulator has certified WuXi Biologics’ DP5 and DPPC sites in Wuxi for commercial production, reinforcing the company’s global GMP-compliant manufacturing capabilities.
Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies
Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.
EQT Life Sciences Exits Vivasure Medical Following Sale to Haemonetics
EQT Life Sciences, formerly known as LSP, one of Europe’s largest life sciences investors, has announced that its LSP Health Economics Fund has exited Vivasure Medical Limited, a Galway-based medical device company, following its acquisition by Haemonetics Corporation, a global medical technology company.
Oricell Therapeutics Raises USD 70M in Series C1 to Advance CAR-T Therapies for Solid Tumors
The funding will accelerate global expansion and clinical development of Oricell’s CAR-T pipeline, including its lead hepatocellular carcinoma programme Ori-C101.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy